Global upstream and midstream chemicals chains Report Interpretation

Overview

This monthly chemicals-chain tracker assesses global upstream and midstream chemical pricing, feedstocks and representative company margins. Morgan Stanley sees stronger August pricing in Asia but uneven profitability across chemical chains, with China’s return to net imports adding a potentially important demand-and-inventory signal.

Core views

Morgan Stanley reports that August chemical prices generally moved higher, with Asia outperforming Europe and the United States. The institution views the stronger Asian price moves as a possible lead indicator for European and US September contract pricing because Asian markets operate more heavily on spot pricing. Rising oil prices and European natural-gas prices could reinforce this direction, although the report also notes that China's return to net-import status could create broader price pressure. China became a net importer of chemicals in July, reversing four months of net exports. Exports declined 15% versus June while imports increased 25%. Morgan Stanley argues that the shift is less likely to reflect stronger end demand because China’s July and August PMIs were both in contraction territory at 49.2 and 49.8, respectively. Instead, it attributes the move mainly to inventory replenishment after lower July chemical prices, alongside normal maintenance activity. This replenishment may have contributed to higher Asian chemical prices, together with Middle East geopolitical tensions. The report finds that tracker margins were flat to lower month on month for the principal European names it tracks. Arkema's tracker margin rose 0.7% month on month and 11.8% year on year, as stronger C3 margins in Europe and the US outweighed weaker Asian C3 margins. Morgan Stanley estimates Arkema's annualized spot EBITDA at €1.7bn, versus Visible Alpha consensus FY26 EBITDA of €1.27bn. BASF's tracker margin declined 0.2% month on month but remained 19.4% above the prior year, with higher Chemicals margins offset by lower Materials margins; its annualized spot EBITDA is estimated at €8.15bn versus €7.73bn Visible Alpha FY26 consensus. Evonik showed the clearest deterioration: its tracker margin fell 14.6% month on month, though it remained 39.2% above the prior year. The decline was driven by substantially lower methionine margins, where modest price declines across the US, Europe and Asia coincided with higher feedstock costs; improved C4 margins only partly offset the effect. Morgan Stanley estimates annualized spot EBITDA at €1.9bn, below Visible Alpha FY26 consensus of €2.0bn. Across petrochemical chains, aggregate C2 prices declined 0.3% month on month while C2 margins fell 8.8%; aggregate C3 prices also fell 0.3% and C3 margins declined 9.6%. Ethylene feedstock prices increased across geographies while downstream C2 prices averaged lower, with ethylene oxide and VAM among the largest declines. Propylene prices fell 3.2% in the US but rose 5.6% in Europe and 12.4% in Asia. In C3, sharp declines in US and European polyether polyols and Asian methionine weighed on margins despite supply disruption at Covestro's Dormagen production site. C4 prices increased 5.3% month on month but margins declined 0.8%, led by higher butadiene prices in the US, Europe and Asia and double-digit price gains for MTBE in Europe and Asia. C6 prices increased 4.2% and margins rose 2.5%; Morgan Stanley highlights Asian nylon margins rising 105% month on month, though still 62% below the prior year, amid tighter global supplies and higher benzene costs. Europe retained a relative cost advantage of $433/t, down from $504/t in July. Meanwhile, the Asia naphtha premium declined to $5.1/bbl from $8.8/bbl in July, although it remained above June's $2.6/bbl and the FY25 average of $3.3/bbl. The report also notes a potential valuation rotation from Industrial Chemicals into Consumer Chemicals, citing an inflection in Consumer Chemicals versus Industrial Chemicals EV/EBITDA. Its overall industry view remains In-Line, reflecting a market where stronger regional pricing and selected margin improvement coexist with weak chain-level margins and uneven end-market conditions.

Analysis framework

Morgan Stanley uses monthly price and feedstock data across global chemical chains to track the spread between selling prices and input costs. It compares month-on-month and year-on-year movements by region, translates representative margin movements into annualized spot EBITDA for BASF, Arkema and Evonik, and uses China trade, PMI and supply indicators to interpret demand, inventory and pricing conditions.

Methodology notes

• Industry AnalysisVolume-price decomposition

  Chemical-chain price, feedstock-cost and margin tracking

  The report compares downstream chemical prices with feedstock costs to show how monthly price movements translate into margin changes across C2, C3, C4 and C6 chains.

• Industry AnalysisSupply-demand framework

  China chemical trade, PMI and inventory-replenishment assessment

  Morgan Stanley interprets China's shift to net imports using export and import changes, weak PMI readings, maintenance activity and inventory behavior rather than treating the trade shift as demand evidence alone.

• Valuation methodsEV/EBITDA valuation

  Consumer Chemicals versus Industrial Chemicals EV/EBITDA comparison

  The report uses EV/EBITDA trends to identify a potential relative valuation rotation from Industrial Chemicals into Consumer Chemicals.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Arkema S.A.

  Tracked chemicals-margin beneficiary

  Strengths

  Tracker margin increased 0.7% month on month, supported by higher C3 margins in Europe and the US.

  Weaknesses

  Higher European and US C3 margins were partly offset by lower Asian C3 margins.

  Comparison

  Outperformed BASF and Evonik on month-on-month tracker-margin movement.

  Risks

  Exposure to regional C3 margin weakness, particularly in Asia.

• BASF

  Tracked chemicals-margin company

  Strengths

  Higher Chemicals margins supported a broadly stable tracker margin and annualized spot EBITDA above consensus.

  Weaknesses

  Lower Materials margins offset stronger Chemicals margins.

  Comparison

  Tracker-margin movement was weaker than Arkema's but substantially better than Evonik's.

  Risks

  Materials-margin deterioration could continue to offset Chemicals-margin gains.

• Evonik Industries AG

  Tracked chemicals-margin company

  Strengths

  Higher C4 margins provided a partial offset; tracker margin remained 39.2% above the prior year.

  Weaknesses

  Methionine-margin weakness drove a 14.6% month-on-month tracker-margin decline.

  Comparison

  Had the weakest month-on-month tracker-margin performance among Arkema, BASF and Evonik.

  Risks

  Further methionine price weakness or feedstock-cost increases could pressure profitability.

Key data

• China chemical exports-15% versus JuneJuly decline as China returned to net-import status.
• China chemical imports+25% versus JuneJuly increase after four months of net exports.
• China PMI49.2 in July; 49.8 in AugustBoth readings were in contraction territory.
• Asia naphtha premium$5.1/bblAugust average, down from $8.8/bbl in July; June was $2.6/bbl and FY25 averaged $3.3/bbl.
• Arkema tracker margin+0.7% MoM; +11.8% YoYAnnualized spot EBITDA estimated at €1.7bn versus €1.27bn Visible Alpha FY26 consensus.
• BASF tracker margin-0.2% MoM; +19.4% YoYAnnualized spot EBITDA estimated at €8.15bn versus €7.73bn Visible Alpha FY26 consensus.
• Evonik tracker margin-14.6% MoM; +39.2% YoYAnnualized spot EBITDA estimated at €1.9bn versus €2.0bn Visible Alpha FY26 consensus.
• Europe relative cost advantage$433/tBelow July's $504/t.

Impact & implications

Morgan Stanley's tracker suggests that stronger Asian pricing may influence September contract pricing in Europe and the US, particularly as oil and European gas costs rise. However, margin effects remain highly chain- and company-specific: Arkema's and BASF's tracked profitability is resilient to relatively stable, while Evonik is exposed to the sharp decline in methionine economics.